We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Briefing for local authorities on the increasing role of community pharmacy in public health, working with councils and other community partners.
Report showing opportunities and challenges for community pharmacy teams to further support the public’s health.
Information relating to the disapplication of falsified medicines under UK Law.
Scientific advice queries on nanomedicines have increased in recent years, particularly on lipid nanoparticles.
Outlines the aim, scope and definitions of the medical technology innovation classification framework.
The Defence and Security Accelerator (DASA) is running a Market Exploration to explore the Non-Compressible Haemorrhage (NCH) environment. To understand who is doing work in this area and possible novel solutions of treatmen…
A document for patients explaining how the highest risk patient groups eligible for new coronavirus treatments will be identified.
Information on how the ACBS factors in the issue of pricing, when reviewing product applications.
We are allowing alternative courses of actions for manufacturing or laboratory equipment during the outbreak.
How the MHRA assesses marketing authorisation applications (MAA) for medicines referred under Article 29.
Actions that trial sponsors should consider to build resilience into clinical trial design
VDEC works with global leaders from all sectors to develop and deliver the vaccine and therapeutic products we need to protect us from infectious diseases.
VDEC responds strategically to AMR pathogens and new emerging threats (fungi, viruses, and bacteria), by determining the most appropriate research goals to combat these pathogens
Qualified Persons (QPs) should follow the below guidance on the flexible approaches we are taking for medicines imported from third countries.
The MHRA is ready to provide any assistance for clinical trials applications submitted for COVID-19
Information for patients, public and healthcare professionals
Guidance for manufacturers on reporting adverse incidents involving breast implants under the vigilance system.
Guidance and specifications for the recording and extraction of CTAD data from laboratories in England processing LA and NHS commissioned chlamydia tests.
Submitting notifications on the European common entry gate for Northern Ireland for suppliers of e-cigarettes and e-liquids.
Types of ingredients permitted in nicotine-containing liquids in electronic cigarettes and refill containers.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).